

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : A61K 37/02		A1	(11) International Publication Number: WO 94/22465 (43) International Publication Date: 13 October 1994 (13.10.94)
(21) International Application Number: PCT/US94/03667		(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 4 April 1994 (04.04.94)			
(30) Priority Data: 08/042,247 2 April 1993 (02.04.93) US			
(71) Applicant: BRIGHAM AND WOMEN'S HOSPITAL [US/US]; 75 Francis Street, Boston, MA 02115 (US).		Published <i>With international search report.</i>	
(72) Inventors: STOSSEL, Thomas, P.; 12 Blake Street, Belmont, MA 02178 (US). LIND, Stuart, E.; 15 Falmouth Circle, Wellesley, MA 02181 (US). JANMEY, Paul, A.; 63 Webcowet Road, Arlington, MA 02174 (US).			
(74) Agents: HALEY, James, F., Jr. et al.; Fish & Neave, 1251 Avenue of the Americas, New York, NY 10020 (US).			
(54) Title: METHOD FOR REDUCING THE VISCOSITY OF PATHOLOGICAL MUCOID AIRWAY CONTENTS IN THE RESPIRATORY TRACT			
(57) Abstract			
<p>The invention is generally directed to methods of promoting normal respiratory tract airflow in patients with restricted airflow and ciliary clearance caused by the presence of pathological airway contents, and particularly mucoid contents. Actin-binding proteins are administered into the respiratory tract of a patient with a pathological respiratory condition involving the presence of such contents. The actin-binding protein binds to actin polymers in the contents and decreases the viscosity. The actin-binding proteins also prevent actin from binding to exogenous or endogenous DNase I, thus increasing the degradation of DNA polymers in the contents.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Larvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

METHOD FOR REDUCING THE VISCOSITY OF PATHOLOGICAL
MUCOID AIRWAY CONTENTS IN THE RESPIRATORY TRACT

The present invention relates to the treatment of respiratory disorders in which it is desired to disaggregate, depolymerize, or solubilize actin filaments or to promote the degradation of DNA in respiratory tract mucus. The invention particularly relates to solubilization and increased clearance of mucus obstructing the respiratory tract in airway diseases. The invention relates to a method for reducing the viscosity of mucus by instillation of actin-binding proteins into the respiratory tract. The invention also relates to a method for facilitating the action of DNase I in respiratory tract treatments by blocking actin binding to DNase I or reducing the levels of actin in respiratory tract mucus. The method involves the administration of efficacious amounts of actin-binding compounds, or fragments or functional derivatives thereof, such that the compounds or fragments or derivatives are active in the respiratory tract of a patient in need of such treatment.

- 2 -

BACKGROUND OF THE INVENTION

Airway Obstruction

Airway obstruction caused by inflammatory exudation is a major cause of morbidity and mortality.

- 5 Mucus plugging and stasis is a feature of chronic bronchitis, asthmatic bronchitis, bacterial bronchopneumonia and, especially, cystic fibrosis, and is associated with destruction of lung substance.
Mucus also contributes to the morbidity of acute and
10 chronic sinusitis and even the common cold.

Mucoid obstruction of the respiratory system is multifactorial. One factor is increased mucus synthesis and release caused by inflammatory mediators elicited by infection or irritation. In cystic
15 fibrosis, the viscosity of mucus is increased, presumably because of abnormal epithelial ion transport which affects the hydration or charge of the ionic polymers composing the mucus substance. The thick mucus of cystic fibrosis prevents bacterial clearance
20 by ciliary transport and favors the growth of bacteria, especially *Pseudomonas aeruginosa*. These bacteria or other irritants, such as tobacco smoke, generate chemoattractants which recruit leukocytes into the airway. As the leukocytes engage bacteria or
25 irritants, they degenerate and their components contribute debris that affect the viscoelasticity of the airway contents.

Much research in the area of pathological mucoid airway contents has focused on DNA, since DNA
30 was originally isolated from pus. However, there has also been research on the mucopolysaccharide composition of mucus and the role of disulfide bonding (Roberts, G.P., Arch. Biochem. Biophys. 173:528-537 (1976); Roberts, G.P., Eur. J. Biochem. 50:265-280

- 3 -

(1974); Charman, J., et al., *Brit. J. Dis. Chest* 68:215 (1974); Bhaskar, K.R., et al., *Exp. Lung Res.* 10:401-422 (1986); Lethem, M.I., et al., *Eur. Respir. J.* 3:19-23 (1990)). Purulent mucus contains about 10-13 mg/ml of DNA, an ionic polymer widely believed to affect the rheologic properties of airway fluids. Bovine pancreatic DNase I, an enzyme that degrades DNA, was tested as a mucolytic agent many years ago. However, it did not enter clinical practice due to side effects induced by antigenicity and/or contaminating proteases. Accordingly, cDNA for human DNase I was cloned and expressed. Recombinant human DNase I was tested as a therapeutic agent. It was shown to diminish the viscosity of cystic fibrosis mucus *in vitro* (Shak, S., et al., *Proc. Natl. Acad. Sci. USA* 87:9188-9192 (1990)). Human DNase I has recently been approved in the United States for treating patients (over the age of five) with cystic fibrosis.

Extracellular Actin

Actin is the most abundant protein in nucleated animal cells and constitutes 10-20% of the protein of many nucleated cells and 30% of the protein of muscle cells. Actin molecules each bind an ATP or ADP molecule and self-assemble into long filaments during which the ATP is hydrolyzed into ADP.

Injury to animal tissues results in the release of actin into the extracellular space. Although approximately half of nonmuscle cell actin is F-actin, (the double-helical, rodlike, filament form of actin which is assembled from G-actin monomers), the ionic conditions of extracellular fluids favor actin polymerization, so that virtually all the actin released from dying cells would be expected to polymerize into filaments if sufficiently concentrated

- 4 -

(greater than a few micrograms per milliliter) (Lind, S.E. et al., *Am. Rev. Respir. Dis.* 138:429-434 (1988)). Actin polymerizes into long, rod-like filaments which are relatively resistant to degradation by proteolytic enzymes. In purified solutions, in the absence of filament-shortening proteins, actin filaments can easily attain lengths of several microns.

Because of the large amounts of actin in cells, the release of actin from dying cells provides sufficient actin to have a significant effect on the microenvironment, either by increasing the viscosity of extracellular fluids, such as mucin, and/or by entrapping cells or by other, as yet unidentified toxic effects. Infusion of extracellular free actin is toxic to animal tissues (Harper, K.D. et al., *Clin. Res.* 36:625A (1988); Haddad, J.G. et al., *Proc. Natl. Acad. Sci. USA* 87:1381-1385 (1990)). If actin released from injured cells were to be bound to an actin-binding protein, such as those discussed below, this actin would remain monomeric or oligomeric.

Actin-Binding Proteins

There are many proteins which naturally associate with actin. For a review of actin-binding proteins, see Stossel, T.P. et al., *Ann. Rev. Cell Biol.* 1:353-402 (1985); Pollard, T.D. et al., *Ann. Rev. Biochem.* 55:987-1035 (1986). However, two proteins, gelsolin and DBP (vitamin D binding protein) are thought to be primarily responsible for binding extracellular actin (Janmey, P.A. et al., *Blood* 70:529-530 (1987)).

Plasma gelsolin (sometimes called brevin) and DBP (also called Gc globulin) are two high affinity actin-binding proteins that exist in plasma. High affinity actin-binding proteins bind actin with a K_d of

- 5 -

less than 10^{-8} . Both gelsolin and DBP bind to actin in blood serum and have actin depolymerizing activity.

DBP preferentially binds monomeric actin while gelsolin preferentially binds actin filaments.

5 Gelsolin is a multifunctional actin-binding protein obtained from mammalian cytoplasm and extracellular fluids. Plasma gelsolin differs from cellular gelsolin by an additional 25 amino acids at the amino terminus of the molecule. Both gelsolins are
10 the products of a single gene. Plasma gelsolin has three actin-binding sites and binds with high affinity to either G-actin or F-actin.

Plasma gelsolin binds a second actin molecule with a higher affinity than it binds a first actin
15 molecule. Thus, it preferentially forms 2:1 complexes over 1:1 complexes and binds filaments in preference to monomers. When added to F-actin, plasma gelsolin severs the filament in a nonproteolytic manner and remains bound to one end of the newly formed filament.
20 If free gelsolin molecules are present, they will sever the actin filament successively until only 2:1 actin-gelsolin complexes are present, thereby rapidly depolymerizing the filament.

Free and complexed (to actin) gelsolin
25 molecules differ in their functional properties. Although free gelsolin can sever actin filaments, actin-gelsolin complexes cannot.

Gelsolin's primary function in the plasma and other extracellular fluids is to sever actin filaments.
30 If gelsolin is present in excess of actin, only gelsolin-actin complexes are formed; if actin is in excess, there are free actin oligomers and gelsolin-actin complexes. The actin severing occurs by way of a nonproteolytic cleavage of the noncovalent bond between
35 adjacent actin molecules. Gelsolin's severing activity

- 6 -

is activated by micromolar Ca⁺⁺ and by pH above 6, and has been shown to be inhibited by phosphatidyl inositol 4,5-bisphosphate (PIP₂) and phosphatidyl inositol-4-monophosphate (PIP). Since extracellular Ca⁺⁺ concentrations are at millimolar levels and extracellular fluids do not normally contain PIP or PIP₂, in a form that inhibits gelsolin, plasma gelsolin is constitutively active in extracellular fluids.

Human extracellular (plasma) gelsolin cDNA 10 has been cloned and sequenced (Kwiatkowski, D.J. et al., *Nature* 323:455-458 (1986); Kwiatkowski, D.J. et al., *J. Cell Biol.* 106:375-384 (1988)). Fragments of the native protein which retain the ability to bind actin have been identified (Bryan, J., *J. Cell Biol.* 15 106:1553-1562 (1988); Yin, H.L. et al., *J. Cell Biol.* 107:465a (1988), abst. no. 2616); Kwiatkowski, D.J. et al., *J. Cell Biol.* 108:1717-1726 (1989); Way, M. et al., *J. Cell Biol.* 109:593-605 (1989)). There is no evidence to suggest that it is genetically polymorphic 20 (except in the uncommon genetic disorder called Finnish-type amyloidosis in which single amino acid mutations are found in plasma gelsolins), indicating that use of recombinant human protein should not lead to immunogenic or other toxic effects. Plasma gelsolin 25 has been detected in many body fluids, suggesting that gelsolin may also be a normal component of airway fluid, at least in states of inflammation.

DBP has also been cloned (Cooke, N.E. et al., *J. Clin. Invest.* 76:2420-2424 (1985); Yang, F. et al., 30 *Proc. Natl. Acad. Sci. USA* 82:7994-7998 (1985)). DBP has a single actin-binding site and binds constitutively to monomeric but not F-actin.

- 7 -

Actin and DNase I

The catalytic activity of DNase I is inhibited by actin, to which the enzyme binds tightly (Lindberg, U., *Biochem. Biophys. Acta* 82:237-248 5 (1964); Lazarides and Lindberg, *Proc. Natl. Acad. Sci. USA* 71:4742-4746 (1974)). Actin comprises about 10% of the protein mass of leukocytes. It follows, therefore, that abundant actin, as well as DNA polymers, might exist in purulent airway contents. If actin does exist 10 in these contents, the efficacy of DNase I in DNA degradation would predictably be reduced by binding to actin present in the very secretions for which DNase I was intended.

Actin filaments alone produce networks of 15 high elasticity, and when interpenetrated within mucus and/or DNA polymers, predictably would contribute to very rigid gels as they do with fibrin (Janmey, P.A., *Blood* 80:928-936 (1992)). Introduction of actin-binding molecules that disaggregate actin filaments, 20 especially by severing actin filaments (Janmey, P.A., *Curr. Opinion Cell Biology* 3:4-11 (1991)) is therefore an attractive approach to reducing the consistency of airway mucus, and especially purulent airway mucus.

Since actin inhibits the catalytic activity 25 of DNase I, actin-binding molecules should also enhance the efficacy of DNase I in degrading DNA by solubilizing actin and facilitating its removal from DNA-containing airway mucus in which DNase I is intended to be effective.

30

SUMMARY OF THE INVENTION

The present invention is based upon the Applicants' consideration that, since leukocytes are a significant component of purulent mucus and actin

- 8 -

comprises about 10% of the protein mass of leukocytes, abundant actin might exist in purulent mucoid airway contents. The invention is also based on the consideration that the efficacy of DNase I in degrading the DNA polymers in purulent mucus would predictably be reduced by binding to actin present in the mucus. Therefore, the effect of both endogenous DNase I and DNase I added for therapeutic purposes would be reduced by binding to actin present in the very secretions for which the enzymes were intended.

Accordingly, the present invention is based upon the Applicant's consideration that the administration of actin-binding compounds, or fragments or functional derivatives thereof, to patients with pathological mucoid airway contents will provide treatment of and protection against obstruction of the respiratory tract. It is therefore an object of the invention to provide a method for depolymerizing actin filaments, preventing actin polymerization, and for decreasing the levels of actin in the respiratory tract of individuals with airway disease.

It is an object of the invention to provide a method for the reduction of viscosity or solubilization of mucoid airway contents, obstructing the normal patency and flow of air in the respiratory tract in individuals with airway disease, and especially inflammatory airway disease.

Accordingly, the invention provides a method to reduce the viscosity or consistency of pathological airway contents by instillation into the respiratory tract of actin-binding compounds, and especially actin-binding proteins which: 1) disaggregate (depolymerize, fragment and dissociate) or prevent aggregation of actin filaments released from disrupted leukocytes and other cells that solidify airway contents, and

- 9 -

especially mucoid airway contents, and/or 2) prevent actin from inhibiting the action of the enzyme DNase I which degrades DNA polymers that increase the viscoelasticity of mucus. The DNase I may be 5 endogenous or supplied for therapeutic purposes by aerosolization or any other appropriate and effective means.

Accordingly, a further object of the invention is reducing the level of actin binding to 10 DNase I in the respiratory tract by the administration of actin-binding compounds, and especially actin-binding proteins, to the respiratory tract. A further object of the invention is to enhance DNA degradation in pathological mucoid airway contents by the 15 administration of actin-binding compounds, and especially actin-binding proteins.

These and other objects of the invention, which will hereinafter become more readily apparent, can be obtained by administering to patients with 20 mucoid airway contents causing airway obstruction, one or more actin-binding proteins or fragments or functional derivatives thereof, in doses and under a regimen that treat the obstruction which occurs after actin and/or DNA release into said contents.

25

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 Dynamic shear moduli of cystic fibrosis sputum. Sputum samples with or without gelsolin or gelsolin fragment were placed between the parallel circular plates of a torsion pendulum (Ferry, 30 J.D. Viscoelastic Properties of Polymers, 3rd Ed., John Wiley & Sons, New York (1980)) and a momentary displacement was applied to the arm attached to the upper sample plate. The dynamic shear modulus, G', was calculated from the frequency and damping of the

- 10 -

resulting free oscillations. G' of actin polymer-containing solutions depends strongly on the average actin filament length (Janmey et al., *Biochemistry* 27:8218-8226 (1988)). 5 1A: Cystic fibrosis sputum alone; 1B: Cystic fibrosis sputum plus gelsolin; 1C: Cystic fibrosis sputum plus gelsolin amino acid fragment 1-260.

10 Figure 2 Shear creep and recovery of cystic fibrosis sputum. Sputum samples with or without gelsolin or gelsolin fragment placed between plates of the torsion pendulum were subjected to a constant shear stress. The subsequent deformation is quantified as the shear compliance, the ratio of shear strain to the imposed stress. Previous studies have shown that the 15 compliance of F-actin increases sharply as the average filament length decreases (Janmey et al., *Biochemistry* 27:8218-8226 (1988)). The abrupt decreases in strain represent release of the applied stress.

20 Figure 3 Dose response curve for gelsolin and DNase I. The change in viscosity of sputum samples with gelsolin or DNase I was measured in a torsion pendulum after 60 minutes of incubation. The change in viscosity with increasing concentration is shown as a percentage of the initial viscosity.

25 Figure 4 Effect of gelsolin combined with DNase I on the viscosity of sputum. The change in viscosity of sputum samples with gelsolin, DNase I or gelsolin and DNase I was measured in a torsion pendulum over a period of 60 minutes after the addition of the 30 compound. The results are shown as a percentage of the initial viscosity over time.

35 Figure 5 Effect of a combination of actin-binding compounds on the viscosity of sputum. The change in viscosity of sputum samples after the addition of gelsolin combined with Gc globulin (vitamin

- 11 -

D binding protein) was measured in a torsion pendulum over a period of 60 minutes after the addition of the compounds. The results are shown as a percentage of the initial viscosity over time.

5

DETAILED DESCRIPTION

The present invention is based on the consideration that airway (respiratory tract) contents may contain actin filaments and DNA polymers which increase the consistency or viscosity of the airway 10 contents and, by doing so, prevent normal clearance and lead to pathological consequences. Accordingly, an object of the invention is to reduce the viscosity or consistency of pathological airway contents by causing the disaggregation or depolymerization of actin 15 filaments, the inhibition of actin polymerization, reduction of actin levels, and the degradation of DNA polymers. Accordingly, in one embodiment of the invention, an actin-binding compound or compounds are introduced into the respiratory tract of a patient 20 whose airway contents contain actin filaments and DNA polymers that contribute to respiratory distress. The actin-binding compound may disaggregate actin, prevent or reduce the polymerization of free monomeric actin, and/or prevent the binding of actin filaments or 25 monomers to DNase I. A general embodiment of the invention is a method for the solubilization or reduction in consistency or viscosity of pathological respiratory contents in the respiratory tract of individuals experiencing respiratory distress as a 30 result of the presence of such contents.

The present invention is further based upon the consideration that airway mucus may contain actin filaments and DNA polymers which increase the consistency or viscosity of this mucus and thus prevent

- 12 -

normal airflow and clearance. Accordingly, it is an object of the present invention to reduce the viscosity or consistency of such mucus by the administration, into the respiratory tract containing such mucus, of an actin-binding compound or compounds. The compound may act by disaggregating (depolymerizing) actin filaments into actin monomers, by binding to actin so as to prevent the binding of actin to DNase I, or both. The compound may also act by preventing the polymerization of actin monomers into filaments. By promoting mucus clearance, the compound ultimately can reduce the levels of actin in the airway contents. Accordingly, in one embodiment of the invention, a method is provided for reducing the consistency or viscosity of airway mucus or solubilizing said mucus, by the introduction of an actin-binding compound or compounds into the respiratory tract of an individual whose respiratory tract contains said mucus.

The present invention is further based upon the consideration that purulent mucus in the respiratory tract contains significant leukocyte contamination such that said mucus contains DNA polymers increasing the consistency or viscosity of said mucus and may contain amounts of actin filaments such that the mucus contributes to airway obstruction, reduced expectoration, and other forms of respiratory distress. Accordingly, it is an object of the invention to reduce the consistency or viscosity of purulent mucus by causing the disaggregation (depolymerization) of actin filaments that may be present in said mucus and by enhancing the degradation of DNA polymers present in said mucus. Therefore, in a preferred embodiment of the invention, the consistency or viscosity of purulent mucus is reduced by introducing into the respiratory tract of an individual

- 13 -

with said mucus, an actin-binding compound or compounds. The actin-binding compounds may produce their effect by depolymerizing actin into actin monomers, binding to actin filaments and monomers so as 5 to prevent their binding to DNase I, or both. The compound may also act by preventing the polymerization of actin monomers into filaments. By promoting mucus clearance, the compound ultimately can reduce the levels of actin in the airway contents.

10 In all embodiments of the invention, if DNase I is present, it can be either endogenous or added exogenously for therapeutic purposes. When it is added for therapeutic purposes, it may be co-administered with the actin-binding compound or 15 compounds or separately.

In further embodiments of the invention, fragments or functional derivatives of the actin-binding compounds are administered to patients with pathological airway contents, mucus, or purulent mucus 20 in their respiratory tracts to protect against obstruction of the respiratory tract or reduction of expectoration.

In the preferred embodiments of the invention, the methods are directed to reducing the 25 consistency of the specific airway contents by introduction into the respiratory tract of a patient in need of such treatment, actin-binding compounds which may do one or more of the following: (1) disaggregate, depolymerize, fragment, and dissociate actin filaments 30 (or prevent aggregation or polymerization of actin monomers and oligomers) released from disrupted leukocytes and other cells that solidify airway contents; (2) prevent actin from inhibiting the action of DNase I which degrades DNA polymers by blocking 35 actin binding to DNase I; (3) ultimately reduce the

- 14 -

level of actin in airway contents by promoting clearance of the contents. It is to be understood that the actin present in respiratory contents, for the purpose of the invention, is extracellular actin in 5 said contents in free monomer or filament form.

In a particularly preferred embodiment of the invention, the methods are practiced with the protein gelsolin or an active fragment or functional derivative thereof. Gelsolin may be introduced into the 10 respiratory tract by routine methods such as those used to administer DNase I to patients with respiratory distress. The treatment is not, however, limited to gelsolin alone. Gelsolin may be co-administered with other actin-binding compounds (preferably vitamin D 15 binding protein) or with DNase I.

In a further embodiment, an actin-binding compound or compounds (preferably gelsolin) may also be introduced into the airway by the intravenous route. The embodiment is based on the consideration that drug 20 delivery by inhalation may be inherently limited in congested airways because of obstruction. Effective solubilization could be expected to enhance drug delivery by inhalation. On the other hand, an assault from the blood side may deliver the drug into alveoli 25 as well as bronchioles and bronchi, such delivery being heightened by chronic inflammation and concomitant increased blood-tissue permeability.

It is known that plasma proteins can enter the airways as evidenced by α -1-antitrypsin therapy of 30 hereditary emphysema. Presumably the efficiency of blood to tissue delivery of plasma proteins is a direct function of blood levels of those proteins. Accordingly, plasma gelsolin levels can be measured to determine if airway binding to actin has had a 35 depleting effect.

- 15 -

It was shown (*Am. J. Path.* 130:261-267 (1988) and *Am. Rev. Resp. Dis.* 138:429-434 (1988)) that plasma gelsolin levels are depressed in experimental lung injury and in clinical ARDS, and others have claimed
5 that there is some relationship between muscle mass and plasma gelsolin concentrations (Yamamoto, H., *Osaka Gas Group Foundation Publication Volume 5:145-147* (1992)). Since the major source of plasma gelsolin is muscle, it may be that levels fall as patients become increasingly
10 cachectic in response to chronic infection and hypoxia.

In all embodiments of the invention in which the efficiency of DNase I is enhanced, the ultimate object of the embodiment is to enhance DNA degradation in pathological airway contents, and particularly in
15 mucus and purulent mucus.

The diseases that are amenable to treatment by the methods of the present invention include, but are not limited to cystic fibrosis, chronic bronchitis, mucopurulent or purulent exacerbation of simple mucoid
20 bronchitis, bronchorrhea, bronchopneumonia, widespread bronchiolitis, purulent pneumonia, pneumonic-alveolar-consolidation, asthma, with or without asthmatic bronchitis with mucus plugging, acute and/or chronic purulent sinusitis, empyema, bronchiectasis,
25 bronchocoele, adult respiratory distress syndrome (ARDS), post-transplantation obliterative bronchiolitis, and allergenic bronchiolitis (fibrosing alveolitus).

In order to provide a clearer and consistent
30 understanding of the specification and claims, including the scope to be given such terms, the following definitions are provided.

The term "respiratory tract" or "airway" would be understood by the skilled artisan to refer to

the tubular and cavernous organs and structures by means of which pulmonary ventilation and gas exchange between ambient air and blood are brought about. This would be understood to include, *inter alia*, the nasal cavity and conchae, the pharyngeal opening of the auditory tube, the pharynx, the larynx, the trachea, the bronchi, and the lungs. The invention is directed to treatment of airway contents, mucus, purulent mucus, etc. in any of the parts of the tract, particularly 5 sub-tracheal.

It would be understood by the ordinary skilled artisan that "airway contents" or "respiratory tract contents" comprise a mixture of substances normally produced by the cells lining the airway (for example, through secretion) or remnants of the cells themselves. Accordingly, the skilled artisan would understand the term "pathological (mucoid) airway contents" or "pathological (mucoid) contents of the respiratory tract" to refer to those contents that contain components leading to structural and functional changes in the airway contents (such as excess actin) which cause abnormal respiratory tract function and/or disease. These include, but are not limited to, mucus, purulent mucus, thick mucus, such as in cystic fibrosis, bacteria, and the like. The components may also be biological components of mucus that alter the properties of mucus and cause disease or distress. The components themselves may be caused by an underlying disease state that contributes to an increase in the amount of normal airway contents or a change in the type of components from the components normally found in airway contents. For example, there may be an imbalance or disproportionate amount of certain components normally found in airway contents (e.g., 10 excess actin). By "respiratory distress" is meant the 15 20 25 30 35

- 17 -

- consequences of pathological airway contents which include, but are not limited to, reduced airflow, obstruction of the airway, reduced respiratory clearance by cilia, reduced respiratory clearance by
- 5 muscular mechanisms such as coughing, clearing the throat, and sneezing, respiratory irritation from prolonged contact with the contents, the retention of leukocyte-derived lytic enzymes, inflammatory mediators, fungi, mycoplasma, bacteria, or other
- 10 microorganisms.

By the term "mucus", the ordinary skilled artisan would understand the free slime of the mucus membranes, composed of secretion of the glands, along with various inorganic salts, desquamated cells, and

15 leukocytes.

By the term "purulent mucus", for the purpose of the present invention, the skilled artisan would understand mucus that is rendered highly viscous, relatively solidified by DNA polymers derived from

20 white blood cells and/or desquamated and/or broken endogenous airway cells.

The phrases "solubilizing (mucoid) airway contents", "solubilizing mucus", or "solubilizing purulent mucus" are intended to mean changing the

25 mechanical properties of said contents, mucus, or purulent mucus so as to render such contents more like a liquid and less like a solid, more compliant, and better able to flow in response to shear stress.

Disaggregation of polymers contributing to the

30 viscosity of these components can also release proteins and other molecules trapped in the interstices of the contents/mucus/purulent mucus gel. The terms "reducing the viscosity" or "reducing the consistency" would also be understood to mean changing the mechanical

35 properties, as described immediately above. The term

- 18 -

"viscosity" would be understood by the skilled artisan to denote a physical property of a substance that is dependent on the friction of its component molecules as they slide by one another. A highly viscous solution 5 would be characterized by a high degree of friction between component molecules, whereas a reduced viscosity would be characterized by a decrease in the degree of friction between component molecules as they slide by each other.

10 By "exogenous DNase" is intended DNase which is added by clinical means to a patient in need of such DNase by virtue of respiratory distress caused by DNA polymers in the patient's respiratory tract.

15 By "endogenous DNase" is intended DNase which is found normally in the respiratory tract of a patient, and particularly in the mucus of said patient's respiratory tract.

20 By the term "enhance DNA degradation" for the purposes of the present invention is intended adding that amount of an actin-binding compound which will bind to actin present in pathological airway contents, mucus, or purulent mucus, which actin, if not exposed to said actin-binding compound, would bind to DNase present in these fluids, inhibiting this DNase from 25 reducing the amount of DNA polymer to allow decreased viscosity, enhanced respiratory airflow, expectoration, and relief from other forms of respiratory distress caused by the airway contents.

30 The term "actin-binding compound" is meant to include any compound, and especially any protein (or peptide), which is capable of binding actin so as to modify any of actin's many functions, including suppressing the ability of actin monomers to polymerize into filaments, to fragment (disaggregate, 35 depolymerize) pre-existing filaments, and to bind to

- 19 -

DNase I. When administered to a patient in need of treatment, the actin-binding compounds of the invention are substantially free of natural contaminants which associate with such compound either *in vivo* (in a 5 prokaryotic or eukaryotic) host, or *in vitro* (as a result of a chemical synthesis). Such compounds include, but are not limited to extracellular actin-binding proteins such as gelsolin and DBP, and intracellular actin-binding proteins such as those most 10 abundant in cells (for example, myosins, tropomyosins, profilin and cofilin) and those most abundant in non-muscle cells. Actin-binding compounds within the scope of the methods of the invention also include but are not limited to a) actin-binding compounds that 15 predominantly sequester actin monomers, that is, bind monomers in a complex which is resistant to polymerization (for example, DBP, profilin, β_4 -thymosin 1, and cofilin); b) actin-binding compounds which sequester monomers and possess filament severing 20 activity (for example, gelsolin, villin, fragmin and severin; c) actin-binding compounds that predominantly block the ends of actin filaments and prevent the exchange of monomers with that end (for example, tropomodulin, capZ, cap 100, ASP-56); and d) actin- 25 binding nonproteinaceous molecules that have such effects on actin (for example, cytochalasin or biologically-active derivatives thereof, that block the ends of actin filaments and which are modified to remain extracellular). The skilled artisan would 30 understand that useful compounds would remain extracellular in order to prevent any toxicity by interaction with functional intracellular actin. Fragments of actin-binding proteins with retained actin filaments severing and/or monomer-sequestering activity 35 are also within the scope of the present invention.

- 20 -

If desired, such compounds may be administered in the form of a pharmaceutically acceptable salt to the animal.

The term "animal" is meant to include all 5 animals in which free actin or actin filaments in the sputum would be detrimental to the physiology of the animal. Foremost among such animals are humans; however, the invention is not intended to be so limiting, it being within the contemplation of the 10 present invention to treat any and all animals which may experience the beneficial effect of the invention.

An "efficacious amount" of an actin-binding compound is one which is sufficient to reduce or eliminate the toxic effects of actin in the respiratory 15 tract contents of an animal. With respect to the present invention, it is the amount of compound effective to solubilize or reduce the viscosity or consistency of pathological airway contents, mucus, or purulent mucus, inhibit actin-binding to DNase I in 20 these liquids or gels, enhance DNA degradation in these liquids or gels, or reduce the consistency of these liquids or gels so as to treat various forms of respiratory distress. An efficacious amount of an actin-binding compound is also that amount which may 25 reduce bacterial content, the incidence of clinical infection, reduce the content of inflammatory mediators, or the content of degradative and cytotoxic enzymes in respiratory distress syndromes causing or caused by these liquids or gels.

30 The amount of the actin-binding molecule to be given, and the duration of therapy, may be determined by monitoring the frequency of exacerbation of symptoms or the deterioration of symptoms, the sputum volume and consistency, the pulmonary functions 35 such as FEV, blood pO₂, pH, pCO₂, total lung capacity,

- 21 -

residual volume tests of air flow, infection rate, etc. The skilled clinician would be familiar with routine monitoring techniques for respiratory treatment.

The amount of aerosolized actin-binding

5 protein may be determined according to those procedures used to determine the doses of DNase inhalation effective for treatment of patients with DNase I. For example, see Aitken, M.L., et al., *J. Am. Med. Assoc.* 267:1947-1951 (1992), particularly page 1948, "Study
10 Design." The dose delivered *in vivo* is related to the effective amount determined *in vitro*. For example, if sputum is successfully solubilized *in vitro* by the amounts exemplified herein (i.e., 2-10 µg/ml), a thousand-fold increase over the *in vitro* dose would be
15 administered (i.e., 2-10 mg/ml). Of course, it would be understood that the amounts and regimens for the administration of actin-binding compounds can be determined readily by those of ordinary skill in the art of treating respiratory disorders. Generally, the
20 dosage of actin-binding compound treatment will vary depending upon considerations such as the type of the actin-binding compound employed, the age of the patient, the health of the patient, the severity of the disease, the kind of concurrent treatment, the extent
25 of tissue damage, the gender of the patient, the duration of the symptoms, counterindications (if any), and other variables understood as needing adjustment by the individual physician. The correct effective dose could routinely be determined by monitoring the airway
30 contents by aspiration or as sputum.

A material is said to be "substantially free of natural contaminants if it has been substantially purified from materials with which it is normally and naturally found before such purification. Examples of
35 natural contaminants with which actin-binding compounds

might be associated are: non-actin-binding peptides, carbohydrates, glycosylated peptides, lipids, membranes, etc. A material is said to be substantially free of natural contaminants if those contaminants 5 normally and naturally found with the substance *in vivo* or *in vitro* are substantially absent from a sample of the material. By "substantially absent" is meant that such contaminants are either completely absent or are present at such low concentrations that their presence 10 (1) does not interfere with the desired therapeutic effect of the active agent (herein the actin-binding compound) in the preparation when such preparation is administered to an animal and (2) does not harm the animal as the result of the administration of such 15 preparation.

The term "administration" is meant to include introduction of actin-binding compounds into the respiratory tract of an animal by any appropriate means known to the medical art, including, but not limited to 20 inhalation of an aerosolized compound, instillation by bronchoscopy, and intravenous infusion.

The actin-binding compounds of the present invention may be co-administered with DNase or one actin-binding compound may be co-administered with one 25 or more distinct actin-binding compounds. By the term "co-administer" is intended that each of at least two compounds be administered during the time frame wherein the respective periods of biological activity overlap. Thus, the term includes sequential as well as 30 coextensive administration of the compounds of the present invention with each other or with DNase I.

The term "pharmaceutically acceptable vehicle" is intended to include solvents, carriers, diluents, and the like, which are utilized as additives 35 to preparations of the actin-binding compounds of the

- 23 -

invention so as to provide a carrier or adjuvant for the administration of such compounds.

The term "treatment" or "treating" is intended to include the administration of actin-binding 5 compounds to a patient for purposes which may include prophylaxis, amelioration, prevention or cure.

The term "fragment" is meant to include any portion of a molecule which provides a segment of an actin-binding compound which is capable of binding 10 actin monomers and/or severing filaments; the term is meant to include actin-binding fragments which are made from any source, such as, for example, from naturally-occurring peptide sequences, synthetic or chemically-synthesized peptide sequences, and genetically 15 engineered peptide sequences. Further, if such fragment is a peptide, a fragment of a peptide of such actin-binding protein is meant to include to any variant of the actin-binding protein.

A "functional derivative" of an actin-binding 20 compound is a derivative which possesses a biological activity that is substantially similar to the biological activity of the actin-binding compound. By "substantially similar" is meant activity which is quantitatively different but qualitatively the same. 25 For example, a functional derivative of an actin-binding protein of the invention would contain the same amino acid backbone as an actin-binding protein but also contains other modifications such as post-translational modifications such as, for example, bound 30 phospholipids, or covalently linked carbohydrate, depending on the necessity of such modifications for the performance of the diagnostic assay or therapeutic treatment. As used herein, the term is also meant to include a chemical derivative of an actin-binding 35 compound. Such derivatives may improve the compound's

- 24 -

solubility, absorption, biological half life, etc. The derivatives may also decrease the toxicity of the molecule, or eliminate or attenuate any undesirable side effect of the molecule, etc. Derivatives and 5 specifically, chemical moieties capable of mediating such effects are disclosed in Remington's *Pharmaceutical Sciences* (1980). Procedures for coupling such moieties to a molecule are well known in the art. The term "functional derivative" is intended 10 to include chemical derivatives, variants, analogs, or pharmaceutically acceptable salts of an actin-binding compound.

A "variant" is meant to refer to a compound substantially similar in structure and biological 15 activity to either the native compound, or to a fragment thereof..

An "analog" of an actin-binding compound of the invention is meant to refer to a compounds substantially similar in function to either the native actin- 20 binding compound or to a fragment thereof. For example, an analog of an actin-binding protein is a protein which does not have the same amino acid sequence as an actin-binding protein but which is sufficiently homologous to an actin-binding protein so 25 as to retain the biological activity of such actin-binding protein.

The term "pharmaceutically acceptable salt" is intended to include salts of the actin-binding compounds of the invention. Such salts can be formed 30 from pharmaceutically acceptable acids or bases, such as, for example, acids such as sulfuric, hydrochloric, nitric, phosphoric, etc., or bases such as alkali or alkaline earth metal hydroxides, ammonium hydroxides, alkyl ammonium hydroxides, etc.

- 25 -

The "biological activity" of the compounds of the invention is their ability to bind actin and modify it into a form which is less toxic to an animal than unmodified actin. Such modification may be the result 5 of the binding of the compounds *per se* or the result of a chemical or enzymatic reaction which results from such binding.

The particular actin-binding molecules that are the subject of the methods of the invention are 10 purified native and recombinant actin-binding proteins, and other non-proteinaceous actin-binding molecules, and biologically-active fragments thereof, which are characterized by the presence of unique actin-binding domains which possess the biological activity of being 15 able to sequester actin in a monomeric form or rapidly to desegregate or depolymerize actin filaments or to cover sites on free actin that are toxic to host cells. Individual actin-binding domains possessing this 20 biological activity may also be produced by synthetic, enzymatic, proteolytic, chemical or recombinant DNA methods.

In a preferred embodiment, gelsolin or actin-binding fragments thereof, or DBP, a combination of gelsolin or actin-binding fragments thereof and DBP, 25 are provided to a patient in need of treatment. Other preferred actin-binding compounds for use in this invention include β_4 thymosin and ASP-56. In a particularly preferred embodiment, gelsolin or actin-binding fragments thereof, or, a combination of 30 gelsolin or actin-binding fragments thereof and vitamin D binding protein are co-administered with DNase I to a patient in need of treatment.

Preparations of the actin-binding proteins of the invention for parenteral administration include 35 sterile aqueous or non-aqueous solvents, suspensions

- 26 -

and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oil, fish oil, and injectable organic esters. Aqueous carriers include water, water-alcohol solutions, 5 emulsions or suspensions, including saline and buffered medical parenteral vehicles including sodium chloride solution, Ringer's dextrose solution, dextrose plus sodium chloride solution, Ringer's solution containing lactose, or fixed oils. Intravenous vehicles include 10 fluid and nutrient replenishers, electrolyte replenishers, such as those based upon Ringer's dextrose and the like.

The actin-binding proteins of the invention may also be administered by means of pumps, or in 15 sustained-release form, especially, when the primary injury is prolonged or delayed rather an acute.

Administration in a sustained-release form is more convenient for the patient when repeated injections for prolonged periods of time are indicated. 20 For example, it is desirable to administer the actin-binding proteins of the invention in a sustained-release form when the methods of the invention are being used to treat a genetic or chronic disease based upon an actin-related disorder so as to maximize the 25 comfort of the patient.

The actin-binding proteins of the invention can be employed in dosage forms such as tablets, capsules, powder packets, or liquid solutions for oral administration if the biological activity of the 30 protein is not destroyed by the digestive process and if the characteristics of the compound allow it to be absorbed across the intestinal tissue.

The pharmaceutical compositions of the present invention are manufactured by means known to 35 those of skill in the art, for example, by means of

- 27 -

conventional mixing, granulating, dragee-making, dissolving, lyophilizing or similar processes. The compositions of the present invention, in and of themselves, find utility in the control of actin-
5 induced physiological damage, be it chronic or acute. The compositions of the invention direct the body's own mechanisms for dealing with excess actin in the bloodstream or extracellular tissues to its maximum potential. In intravenous dosage form, the
10 compositions of the present invention have a sufficiently rapid onset of action to be useful in the acute management of potential tissue damage.

Actin-binding proteins which are substantially free of natural contaminants can be
15 isolated and purified from their natural or recombinant sources in accordance with conventional conditions and techniques in the art previously used to isolate such proteins, such as extraction, precipitation, chromatography, affinity chromatography,
20 electrophoresis, or the like.

One of skill in the art can identify the actin-binding domain(s) of an actin-binding compound using techniques known in the art, without undue experimentation, and such domains are preferred in the
25 methods of the invention. For example, derivatives of the native actin-binding proteins, or, derivatives of recombinantly produced actin-binding proteins, can be made by proteolytic cleavage of the full-length actin-binding protein with common proteases, such as, for
30 example, trypsin, chymotrypsin, and subtilisin. Affinity chromatography with actin-derivatized resins may be used to assay such fragments for their actin-binding ability.

When identification of compounds or fragments
35 thereof which possess actin-severing activity is

desired, such compounds or fragments can also be identified using techniques known in the art, for example, by following the rate of depolymerization of pyrene-labeled F-actin.

5 Further, such fragments may be identified by their homology to other known actin-binding or actin-severing domains wherein it may be predicted that function will follow homology. For example, it is known that severin, gelsolin and villin, and especially 10 amino acid residues 40-351 in severin and amino acid residues 63-383 in gelsolin, show extensive homology in the domain responsible for F-actin severing activity.

The N-terminal half of gelsolin, for example, an N-terminal tryptic fragment known as CT45, is 15 capable of severing F-actin and contains two actin binding sites. Efficacious amounts of CT45 which are substantially free of natural contaminants can be administered to a patient. One of these sites resides in a chymotryptic fragment, CT15N (human gelsolin 20 residues 24-150), which binds the ends of actin monomers and filaments with high affinity; the other site is contained in the adjacent fragment CT28N (residues 151-406), which binds to the side of F-actin 25 in a polyphosphoinositide-regulated manner. Neither of the fragments sever actin filaments by themselves. The smallest gelsolin polypeptide which is capable of severing F-actin encompasses residues 25-165 of plasma gelsolin.

Further, compounds such as actin-binding 30 proteins are highly conserved among species and can be easily isolated in large quantities from nonhuman (bovine, porcine) plasma and/or muscle tissues and fragments of these proteins can be chemically or enzymatically prepared by techniques well-known in the 35 art. Thus such actin-binding compounds can be

- 29 -

administered to a patient in need of the therapeutic methods of the invention without provoking a severe immune response.

All references cited in this application are
5 incorporated herein by reference. Having now generally described the invention, the following examples further describe the materials and methods used in carrying out the invention. The examples are not intended to limit the invention in any manner.

10 Example 1

Specimens of expectorated sputum from patients with cystic fibrosis, some of whom had received aerosolized DNase I, were thawed and separated into sections. The procedure described by Shak et al.
15 (*Proc. Natl. Acad. Sci. USA* 87:9188-9192 (1990)) for determining the effect of DNase I on sputum consistency was followed, except that instead of adding DNase I, purified plasma gelsolin was added. This protein non-covalently severs actin polymers. A recombinant
20 gelsolin fragment produced in *E. coli* and encompassing amino acid residues 1-260 of gelsolin ("gelsolin 260"), capable also of fragmenting actin filaments, was also used. These proteins, which have no known effects on DNA, essentially gave the same results described by
25 Shak et al., (*Proc. Natl. Acad. Sci. USA* 87:9188-9192 (1990)) in the pourability test for cystic fibrosis sputum. The gelsolin fragment was more effective than gelsolin, although it was added at a three-fold higher concentration (Table 1).

- 30 -

Table 1

Sputum samples of about 150 mg were divided by cutting with a razor blade and placed in test tubes containing the indicated additives in 50 mL volumes. Samples were incubated at 37°C in test tubes which were inverted at the time intervals shown in the table, and the presence and extent of movement noted of sputum following a tap on the side of the tube; 0 = no movement; Tr = <10% of the sputum moved down the side of the inverted tube; 1+ = 10-20% of the sputum moved; 2+ = 20-50% of the sputum moved, 3+ = >50% of the sputum moved; 4+ = all of the sputum moved.

	Additive	0 min	15 min	30 min	60 min
10	0.15 M NaCl	0	Tr	Tr	Tr
	+0.5 mM gelsolin	0	2+	3+	4+
	+5 mM gelsolin fragment	0	3+	4+	4+

The experiments were repeated with additional samples of sputum, and gave identical results. Boiled 15 gelsolin fragment was inactive.

Example 2

Sputum samples were studied with a more formal rheological assay involving a torsion pendulum. As shown in Figure 1A, cystic fibrosis sputum was very 20 rigid and elastic, as indicated by the high frequency oscillations induced by a transient stress, from which an elastic modulus (G') of could be calculated. Addition of gelsolin (1B) and gelsolin fragment (1C) reduced the frequency of the oscillations, lowering the 25 moduli 3- and 10-fold respectively. Again, the fragment, present in higher concentration, was more effective than gelsolin. The strain response (known as "creep") of sputum to a steady stress showed the inherent stiffness or poor compliance of cystic 30 fibrosis sputum, whereas gelsolin and gelsolin fragment, again in a dose-response manner, increased the creep compliance. All samples, however, recovered their original positions following the removal of the

- 31 -

stress, indicating that coherent polymers, possibly mucopolysaccharides and DNA, remained in the gels.

Example 3

Rhodamine phalloidin, which binds to 5 polymeric actin, was added to cystic fibrosis sputum specimens which were then observed in the phase contrast and fluorescence microscopes. The samples contained cellular debris, the presumed source of DNA and actin, and were brightly fluorescent. Untreated 10 and gelsolin-fragment-treated sputum plugs were diluted in 2.5 ml of 0.15 M NaCl solution and centrifuged. The absorbance at 280 nm was determined as an indication of how much protein was released from the sputum gels. The results are shown in Table 2 and show that gelsolin 15 and the 260 kDa fragment released protein from the sputum plugs.

Table 2

Sample	OD @ 1 = 280 nm (OD)
Sputum alone	0.015
Sputum + 1.5 mM gelsolin	0.249
Sputum + 2.1 mM 260 fragment	0.247

Analysis of protein released from cystic fibrosis sputum gels incubated with gelsolin. Samples of 50 μ l from the supernatant solutions on which the 25 optical densities had been determined were added to an equal volume of sodium dodecyl sulfate- and β -mercaptoethanol-containing buffer solution, and polypeptides in this mixture were resolved by polyacrylamide gel electrophoresis. The gel was 30 stained with Coomassie blue. The gel showed that the gelsolin- and gelsolin fragment-containing solutions contained many different proteins and large amounts of

- 32 -

three proteins, including one co-migrating with actin used as a molecular weight standard, than with the control supernatant.

Anti-actin antibody immunoblot study of cystic fibrosis sputum. Duplicates of cystic fibrosis sputum from two different patients were suspended in an equal volume of 0.15 M sodium chloride 20 mM Tris-HCl, pH 7.0, and homogenized. 50 µL of the material was added to an equal volume of SDS gel buffer and resolved by electrophoresis on a polyacrylamide gel. The gel polypeptides were transferred to nitrocellulose and the actin band identified with an anti-actin antibody. Bands were seen in the lanes containing the sputum. This result confirms that actin is present in cystic fibrosis sputum.

Example 4

Solubilization of Purulent Sputum by Actin-Binding Proteins. Samples of fresh sputum from CF patients were obtained and tested within a few hours of collection. In this test, commercial bovine DNase I was compared directly with purified plasma gelsolin in the pourability assay (Table 3):

Table 3						
	Gelsolin			DNase I		
	Concentration, µg/ml					
Time of incubation at 37°C	2	5	10	2	5	10
1 min	0	0	3+	0	0	0
3 min	0	Tr	3+	0	0	Tr
5 min	Tr	2+	4+	Tr	Tr	Tr
10 min	Tr	2+	4+	Tr	Tr	2+
15 min	Tr	2+	4+	Tr	1+	3+

- 33 -

Since the molecular weight of DNase I is 31,000 and that of gelsolin, 84,000, gelsolin is considerably more effective on a weight basis. Also, the rapid onset of action is consistent with a stoichiometric action expected for gelsolin, whereas the slower onset for DNase more consistent with depolymerization by end loss of monomers rather than fragmentation of actin polymers or enzymatic action on DNA.

10 Effect of Gelsolin and DNase I Concentration on the Viscosity of CF Sputum. To compare the effect of concentration of gelsolin and DNase I on the viscosity of CF sputum, we measured the change in viscosity of sputum samples after the addition of 15 varying concentrations of those compounds.

Sputum samples were collected from CF patients by expectoration and were either tested immediately or frozen in liquid nitrogen and stored at -20°C. The stored samples had rheological 20 properties indistinguishable from those of fresh specimens.

Viscosity was measured in a torsion pendulum and values were computed from the rate of creep of the sample at a stress of 125 mPa, as described in P.A. 25 Janmey, J. Biochem. Biophys. Methods, 22:41 (1991). Uniform plugs of .25 ml were cut from coherent masses of the sputum samples and the plugs were layered onto round cover-slips. Ten microliters of Buffer A without additives or Buffer A with 50, 75 150, 250 or 500nM 30 purified, human gelsolin or with 100, 250, 500, 600 or 750 nM, bovine pancreatic DNase I (Worthington Biochemical, Freehold, New Jersey) were added to the sputum samples. After a 60-minute incubation, the viscosity of the sputum sample from each patient was

- 34 -

measured in duplicate at each concentration of additive.

As shown in Table 4 and in Figure 3, gelsolin caused a marked decrease in viscosity even at the 5 lowest concentration. In contrast, DNase I had no effect on the viscosity of the sputum at concentrations of up to 500nM.

Table 4

Additive Concentration (nM)	% Initial Viscosity	
	Gelsolin	DNase I
50	69	—
75	30	—
100	—	100
150	28	—
250	28	102
500	30	105
600	—	62
750	—	30

Example 5

20 *Synergy Between DNase I and Gelsolin --*
Concentration-dependent release of proteins. A protein release experiment was done that showed concentration-dependent dissolution of sputum samples from three cystic fibrosis patients. Sputum samples of about 25 equivalent volume were suspended in 0.5 ml of a 0.15 M NaCl solution containing purified plasma gelsolin concentrations of approximately 2.0 µg/ml, 4 µg/ml, 7 µg/ml, and 21 µg/ml. After incubation at 37°C for 30

- 35 -

minutes, the samples were centrifuged and the optical density ($\lambda = 280\text{nm}$) of the supernatant solutions were determined. On a relative scale, the A_{280} readings were as follows: 2 $\mu\text{g}/\text{ml}$: 0.25; 4 $\mu\text{g}/\text{ml}$: 1.30; 7 $\mu\text{g}/\text{ml}$: 5 1.86; 21 $\mu\text{g}/\text{ml}$: 180. The A_{280} after 4 $\mu\text{g}/\text{ml}$ DNase I was approximately 0.5. The A_{280} after 4 $\mu\text{g}/\text{ml}$ DNase I plus 2 $\mu\text{g}/\text{ml}$ gelsolin was approximately 1.3. Gelsolin produced more dissolution expected at a low dose in the presence of a basally ineffective DNase I 10 concentration.

Effect of Gelsolin Combined with DNase I On the Viscosity of CF Sputum. To determine whether the combination of gelsolin with DNase I shows synergy in reducing the viscosity of CF sputum, we measured the 15 viscosity of sputum samples over time after the addition of one or both compounds.

Sputum samples were collected from CF patients by expectoration and were either tested immediately or frozen in liquid nitrogen and stored 20 at -20°C. The stored samples had rheological properties indistinguishable from those of fresh specimens.

Viscosity was measured in a torsion pendulum and values were computed from the rate of creep of the 25 sample at a stress of 125 mPa, as described in P.A. Janmey, J. Biochem. Biophys. Methods, 22:41 (1991). Uniform plugs of .25 ml were cut from coherent masses of the sputum samples and the plugs were layered onto round cover-slips. Ten microliters of Buffer A without 30 additives, with 250 nM purified human gelsolin, 250 nM bovine pancreatic DNase I (Worthington Biochemical, Freehold, New Jersey) or with a 250nM combination of gelsolin and DNase I were then added to each sample. The cover-slips were then pressed against the suspended

- 36 -

plate of the torsion pendulum. Duplicate measurements of the viscosity of the sputum sample from each patient were made 15, 30, 45 and 60 minutes after the addition of the buffer.

5 As shown in Figure 4, gelsolin combined with DNase I caused a greater reduction in the viscosity of the sputum than did gelsolin alone. DNase I at the same concentration had no effect on the viscosity of the samples. The viscosity of sputum samples from the 10 same patient that were treated with Buffer A alone did not vary over the course of the experiment.

Example 6

Effect of a Combination of Actin-Binding Compounds on CF Sputum. To test the effect of a 15 combination of actin-binding compounds on the viscosity of CF sputum, we measured the change in viscosity over time of sputum samples after the addition of gelsolin combined with Gc globulin (vitamin D binding protein).

Thirty-two sputum samples were obtained from 20 5 CF patients. The samples were either studied immediately or were frozen in liquid nitrogen and stored at -20°C. The stored samples had rheological properties indistinguishable from those of fresh specimens.

Viscosity was measured in a torsion pendulum 25 and values were computed from the rate of creep of the sample at a stress of 125 mPa, as described in P.A. Janmey, J. Biochem. Biophys. Methods, 22:41 (1991). Uniform plugs of .25 ml were cut from coherent masses 30 of the sputum samples and the plugs were layered onto round cover-slips. Ten microliters of Buffer A without additives or with a 250 nM combination of purified human gelsolin and Gc globulin (Calbiochem, La Jolla, California) were then added to each sample and the

- 37 -

cover-slips were pressed against the suspended plate of the torsion pendulum. Duplicate measurements of the viscosity of the sputum sample from each patient were made 15, 30, 45 and 60 minutes after the addition of 5 the buffer.

As shown in Figure 5, gelsolin combined with Gc globulin rapidly reduced the viscosity of the sputum samples. The viscosity of sputum samples from the same patient that were treated with Buffer A alone did not 10 vary over the course of the experiment.

Now, having fully described this invention, it will be understood by those with skill in the art that the scope may be performed within a wide and equivalent range of condition, parameters, and the 15 like, without affecting the spirit or scope of the invention or of any embodiment thereof.

WE CLAIM:

1. A method for solubilizing pathological airway contents, mucus or purulent mucus in the respiratory tract of a patient, comprising the step of administering efficacious levels of one or more actin-binding compounds other than DNase I, or fragments or functional derivatives thereof, into the respiratory tract of the patient.
2. A method for reducing the viscosity of pathological airway contents, mucus or purulent mucus in the respiratory tract of a patient, comprising the step of administering efficacious levels of one or more actin-binding compounds other than DNase I, or fragments or functional derivatives thereof, to the patient.
3. A method of treating respiratory tract obstruction in a patient wherein said obstruction is caused by the presence of pathological airway contents, mucus or purulent mucus in the respiratory tract, comprising the step of administering efficacious levels of one or more actin-binding compounds other than DNase I or fragments or functional derivatives therof, to the patient.
4. The method according to any one of claims 1 to 3, wherein at least one actin-binding compound possesses actin filament severing activity.
5. The method according to claim 4, wherein the actin-binding compound or compounds are selected from the group consisting of gelsolin, villin, fragmin and severin.

- 39 -

6. The method according to claim 4, wherein the actin-binding compound is gelsolin or an active fragment or functional derivative thereof.

7. The method according to claim 6, wherein the active fragment is the chymotryptic fragment CT45.

8. The method according to claim 6, wherein the active fragment contains amino acid residues 25-165 of gelsolin.

9. The method according to any one of claims 1 to 3, wherein at least one actin-binding compound sequesters actin monomers in complexes that resist polymerization.

10. The method according to claim 9, wherein the actin-binding compound or compounds are selected from the group consisting of vitamin D binding protein, cofilin, profilin and depactin.

11. The method according to any one of claims 1 to 3, wherein one actin-binding compound is gelsolin or an active fragment or a functional derivative thereof, and another actin-binding compound is vitamin D binding protein.

12. The method according to any one of claims 1 to 3, wherein DNase I is co-administered to the patient.

13. The method according to any one of claims 1 to 3, wherein said pathological airway contents, mucus or purulent mucus is associated with a pathological respiratory condition selected from the

- 40 -

group consisting of cystic fibrosis, chronic bronchitis, mucopurulent or purulent exacerbation of simple mucoid bronchitis, bronchorrhea, bronchopneumonia, widespread bronchiolitis, purulent pneumonia, pneumonic-alveolar-consolidation, asthma, with or without asthmatic bronchitis with mucus plugging, acute and/or chronic purulent sinusitis, empyema, bronchiectasis, bronchocoele, adult respiratory distress syndrome (ARDS), post-transplantation obliterative bronchiolitis, and allergic bronchiolitis (fibrosing alveolitus).

14. A pharmaceutical composition comprising one or more actin-binding compounds and a pharmaceutically acceptable carrier for administration to a patient suffering from a pathological respiratory condition.

15. A pharmaceutical composition according to claim 14 wherein the actin-binding compound or compounds are selected from gelsolin or a fragment or functional derivative thereof, vitamin D binding protein, and a combination of gelsolin or a fragment or functional derivative thereof and vitamin D binding protein.

16. A pharmaceutical composition according to claim 15 wherein the gelsolin fragment is the chymotryptic fragment CT45.

17. A pharmaceutical composition according to claim 15 wherein the gelsolin fragment comprises amino acid residues 25 to 165 of plasma gelsolin.

1/3




FIG. 1A




FIG. 1B




FIG. 1C

SUBSTITUTE SHEET (RHF F 261)

2/3




FIG. 2




FIG. 3

SUBSTITUTE SHEET (RULE 26)

3/3




FIG. 4




FIG. 5

SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 94/03667

A. CLASSIFICATION OF SUBJECT MATTER
IPC 5 A61K37/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 5 A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO,A,91 15770 (THE GENERAL HOSPITAL CORPORATION) 17 October 1991 see the Claims ---	1,14-17
X	THE AMERICAN REVIEW OF RESPIRATORY DISEASE vol. 138, no. 2 , August 1988 , NEW YORK pages 429 - 434 LIND S.E. ET AL. 'Depression of Gelsolin Levels and Detection of Gelsolin-Actin Complexes in Plasma of Patients with Acute Lung Injury' see the whole document ---	1-17 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

8 July 1994

Date of mailing of the international search report

14.07.94

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentiaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Moreau, J

INTERNATIONAL SEARCH REPORT

International application No. PCT/US 94/03667
--

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA vol. 87, no. 23 , December 1990 , WASHINGTON US pages 9188 - 9192 SHAK S. ET AL. 'Recombinant DNase I reduces the viscosity of cystic fibrosis sputum' see the whole document --- WO,A,94 04704 (BRIGHAM AND WOMEN'S HOSPITAL) 3 March 1994 see the whole document -----	1,12
P,X		1,14-17

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US 94/03667

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
WO-A-9115770	17-10-91	AU-A-	7751691	30-10-91	
		EP-A-	0526544	10-02-93	
		US-A-	5260224	09-11-93	
-----	-----	-----			-----
WO-A-9404704	03-03-94	NONE			-----
-----	-----	-----			-----